Ray of hope for blood cancer, lymphoma patients as CAR-T cell therapy to be available in India – Moneycontrol

My Account
Follow us on:
Powered By Finity
Discover 5000+ schemes. Track your portfolio 24X7
Invest Now
MC30 is a curated basket of 30 investment-worthy
mutual Fund (MF) schemes.
Invest Now
Powered By Wazirx
The new age digital currency to diversify a portfolio.
Invest Now
Visit this section to access live price and charts.
Invest Now
Learn and stay informed about cryptocurrency in India.
Learn More
Powered By
Learn, discover & invest in smallcases across different types to build your long term portfolio.
Invest Now
Explore from India`s leading investment managers and advisors curating their strategies as smallcases.
Invest Now
Powered By stockal
Diversify your portfolio by investing in Global brands.
Invest Now
Pre-configured baskets of stocks & ETFs that you can invest
in with a single click. Developed by hedge funds, global
asset management companies, experienced wealth
management firms and portfolio managers.
Invest Now
Gamechangers
AMBAREESH BALIGA
Fundamental, Stock Ideas, Multibaggers & Insights
Subscribe
CK NARAYAN
Stock & Index F&O Trading Calls & Market Analysis
Subscribe
SUDARSHAN SUKHANI
Technical Call, Trading Calls & Insights
Subscribe
T GNANASEKAR
Commodity Trading Calls & Market Analysis
Subscribe
MECKLAI FINANCIALS
Currency Derivatives Trading Calls & Insights
Subscribe
SHUBHAM AGARWAL
Options Trading Advice and Market Analysis
Subscribe
MARKET SMITH INDIA
Model portfolios, Investment Ideas, Guru Screens and Much More
Subscribe
TraderSmith
Proprietary system driven Rule Based Trading calls
Subscribe
Moneycontrol  PRO
Moneycontrol  PRO
Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
Subscribe
Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
Explore
STOCK REPORTS BY THOMSON REUTERS
Details stock report and investment recommendation
Subscribe
POWER YOUR TRADE
Technical and Commodity Calls
Subscribe
INVESTMENT WATCH
Set price, volume and news alerts
Subscribe
The first CAR-T cell therapy, a type of gene therapy, to treat cancers of blood and lymphatic system is likely to be available in India from 2023, offering hope to patients who can’t afford to travel abroad for the expensive treatment.
On June 11, ImmunoACT, an Indian Institute of Technology, Bombay spin-off company, launched its facility to start production on a large scale. As of now, CAR-T cell therapy is not available in India, Patients have to travel to countries like the US and it costs nearly Rs 3-4 crore.
The indigenously developed CAR-T cell therapy was the result of intense research over the last eight years and had now been patented, Rahul Purwar, a senior IIT-Bombay faculty who is also the founder and CEO of ImmunoACT, said.
Incubated at the Society of Innovation and Entrepreneurship at IIT-B, ImmunoACT now has Hyderabad-based pharmaceutical major Laurus Labs as a partner and is looking to make the treatment available at Rs 20-30 lakh a patient in India, the company said.
The facility has the capacity to treat nearly 1,200 patients a year.
As part of the therapy’s Phase-1 clinical trial at Tata Memorial Hospitals’ Advanced Centre for Treatment, Research and Education in Cancer in Mumbai, 10 lymphoma patients have been treated with no relapse so far.
The company is now looking to seek regulatory approvals from the Central Drugs Standard Control Organisation for Phase 2 trials with about 40 patients.
In its initial trials, the project received support from the Centre’s department of biotechnology and Biotechnology Industry Research Assistance Council.
What is CAR-T Cell therapy?
Chimeric Antigen Receptor (CAR)- T cells are a patient’s own immune cells, which are engineered in the laboratory to fight cancer.
It is mostly effective in blood cancer and lymphoma (cancer beginning in the cells of the lymph system), though studies are on to assess its role in solid tumours and auto-immune diseases as well.
Also read: Explainer | Dostarlimab for cancer cure: Hope or hype?
As of now, the therapy is usually offered as second-line treatment for late-stage leukemia and lymphoma patients who are either not responding to conventional treatments like chemotherapy and bone-marrow transplant or have a case of relapsed cancer.
Research from abroad has shown that the therapy can be effective in 40-50 percent of the patients, with slightly better results in pediatric populations.
Estimates suggest that about 40,000-50,000 new leukemia and lymphoma patients are diagnosed in India every year.
Ray of hope for cancer patients in India
According to Puwar, ImmunoACT’s patented CAR-T cell platform provides a unique design algorithm to develop novel CAR-T cells and its first product, HCAR19, showed favourable balance of efficacy and toxicity.
“It can be offered to patients with CD19 marker in B cells (the protein that is used to diagnose cancers that arise from B type of cell–white blood cells that produce antibodies such as B cell lymphomas, acute lymphoblastic leukemia, and chronic lymphocytic leukemia),” said Purwar.
He said that the majority of B cell malignancies have normal to high levels of CD19.
Also read:  Current surge in Covid-19 cases not start of fourth wave, say authorities
The majority of the commercially available CAR-T cell therapies are also associated with severe toxicity, Purwar said, adding the therapy developed in India was far better on that count.
He also said that the therapy was likely to be available at cancer hospitals after the Phase 2 trial of the research projects, while the late-stage trial would continue concurrently.
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported